Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade

Jordan Bury; Matthew Zirwas

doi:10.36849/JDD.7249

Unexpected Clinical Lessons Learned From IL-4 and IL-13 Blockade

J Drugs Dermatol. 2023 Oct 1;22(10):1007-1008. doi: 10.36849/JDD.7249.

Authors

Jordan Bury, Matthew Zirwas

PMID: 37801527
DOI: 10.36849/JDD.7249

Abstract

In 2017, dupilumab became the first FDA approved systemic therapy for atopic dermatitis. Since its approval, extensive clinical experience and continued research have revealed a number of unexpected effects that are highly clinically relevant. We will review these clinical effects and the supporting evidence.J Drugs Dermatol. 2023;22(10):1007-1008 doi:10.36849/JDD.7249.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal* / pharmacology
Antibodies, Monoclonal* / therapeutic use
Dermatitis, Atopic* / drug therapy
Humans
Interleukin-13 / therapeutic use
Interleukin-4 / therapeutic use
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal
Interleukin-13
Interleukin-4